Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...

Spooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...

Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

The pharma industry registered a 7.5% value growth year-on-year for the month of February, with sales of ₹18,781 crore, ...

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, ...

Ltd, and Intas Pharmaceuticals Ltd, with some of the companies getting price fixed for multiple strengths of the combination drug. Besides, prices has been fixed for other anti-diabetes drug ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Try Now>> See the top stocks recommended by analysts >> Read More on PHAT: Phathom Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

“When you really start to dig deeper and see where the proliferation is coming from, you start to notice that it’s on the pollution of the pharmaceutical factories,” she explains.